Provable elimination of information leakage through timing channels. This project aims to develop techniques to solve the issue in information security of unauthorised information flow resulting from competition for shared hardware resources. The project will combine operating systems design, formal hardware models, information-flow reasoning and theorem proving to achieve a goal that is widely considered infeasible. The project is expected to result in a system that prevents leakage of critical ....Provable elimination of information leakage through timing channels. This project aims to develop techniques to solve the issue in information security of unauthorised information flow resulting from competition for shared hardware resources. The project will combine operating systems design, formal hardware models, information-flow reasoning and theorem proving to achieve a goal that is widely considered infeasible. The project is expected to result in a system that prevents leakage of critical information, such as encryption keys, through timing channels. This should prevent sophisticated attacks on public clouds, mobile devices and military-grade cross-domain devices.Read moreRead less
The rise of mistrust: Digital platforms and trust in news media. This project aims to investigate how trust and mistrust in news changes audiences’ behaviours as they increasingly access news through digital platforms. Observing the global crisis of trust, the project will undertake a longitudinal analysis of trust and mistrust in news, a four-country experiment that links trust and audience responses, and an in-depth qualitative study that provides specific contexts of these choices. The resear ....The rise of mistrust: Digital platforms and trust in news media. This project aims to investigate how trust and mistrust in news changes audiences’ behaviours as they increasingly access news through digital platforms. Observing the global crisis of trust, the project will undertake a longitudinal analysis of trust and mistrust in news, a four-country experiment that links trust and audience responses, and an in-depth qualitative study that provides specific contexts of these choices. The research will directly benefit policy makers, as it addresses questions of how to better secure trustworthy news content in an age of increasing dominance of digital platforms that algorithmically sort the range of news available to the Australian public.
Read moreRead less
Grey literature, policy innovation and access to knowledge: realising the value of informal publishing. This project examines the growth of informal research publishing, 'grey literature' in Australia, and the policies and practices that shape it. The project will make recommendations for producers, collecting institutions and policy-makers on how to maximise the considerable social and cultural benefit of 'grey literature'.
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Early Career Industry Fellowships - Grant ID: IE230100647
Funder
Australian Research Council
Funding Amount
$358,175.00
Summary
Improving the accountability of dark advertising on digital platforms. This project aims to improve accountability of dark alcohol advertising on digital platforms. Digital marketing practices are largely opaque, posing a critical challenge for regulation which traditionally relies on advertising being observable as a foundation for public accountability. This project will develop and translate cutting-edge approaches for monitoring dark advertising, building tools and expertise to observe digit ....Improving the accountability of dark advertising on digital platforms. This project aims to improve accountability of dark alcohol advertising on digital platforms. Digital marketing practices are largely opaque, posing a critical challenge for regulation which traditionally relies on advertising being observable as a foundation for public accountability. This project will develop and translate cutting-edge approaches for monitoring dark advertising, building tools and expertise to observe digital advertising and ensure consumer protection and fair market practices in the digital era. The project benefits researchers, civil society, government and the public by providing new methods to examine and monitor harmful digital marketing practices and informing regulatory solutions to mitigate harms.Read moreRead less
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Targeting An Ion Pump In The Malaria Parasite With Multiple Compound Classes
Funder
National Health and Medical Research Council
Funding Amount
$384,686.00
Summary
Large-scale antimalarial drug screening projects have identified three different classes of compound that kill the malaria parasite at extremely low doses and which hold real promise as next-generation antimalarials. Genetic evidence, as well as preliminary data from our own lab, has led us to the hypothesis that all three compound classes exert their antimalarial effect by blocking a molecular ion pump on the parasite surface. The aim of this study is to test this.